Destiny Pharma has recently established two new medicine product programs for infection prevention using biotherapeutic products.
In November 2020, Destiny Pharma acquired the global rights to a Phase 3 ready Clostridioides difficile asset, NTCD-M3, for the prevention of C. difficile infection (CDI) recurrence. More information on CDI can be found here and more information about NTCD-M3 can be found here and here. By acquiring the global rights for NTCD-M3, Destiny Pharma extends its biotherapeutics portfolio alongside the SPOR-COV COVID-19 preclinical asset . These two programs strengthen the Company’s focus on the prevention of infections and is in line with the Board’s strategy to build a world leading anti-infection Company.
In September 2020 the Company announced a new collaboration with SporeGen Limited, to co-develop SporeGen’s SPOR-COV product as a novel, preventive treatment for COVID-19. Destiny and SporeGen have secured funding for the research program via an Innovate UK grant award of £800,000. The SPOR‑COV product consists of a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray. More information can be found here and here.